Prevalence of Baseline Cardiac Arrhythmias in Participants with Overweight or Obesity in Phase 1 Clinical Trials: Analysis of 24-Hour Holter Electrocardiogram Recordings.

Autor: Skovgaard D; Novo Nordisk A/S, Søborg, Denmark., Haahr PM; Novo Nordisk A/S, Søborg, Denmark., Lester R; Celerion, Tempe, Arizona, USA., Clark K; Celerion, Tempe, Arizona, USA., Paglialunga S; Celerion, Tempe, Arizona, USA., Finer N; Novo Nordisk A/S, Søborg, Denmark., Friedrichsen MH; Novo Nordisk A/S, Søborg, Denmark., Hjerpsted JB; Novo Nordisk A/S, Målev, Denmark., Engelmann MDM; Novo Nordisk A/S, Søborg, Denmark.

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2023 May; Vol. 63 (5), pp. 539-543. Date of Electronic Publication: 2023 Jan 20.

Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.

Autor: Hjerpsted JB; Novo Nordisk A/S, Søborg, Denmark., Flint A; Novo Nordisk A/S, Søborg, Denmark., Brooks A; Covance Clinical Research Unit Ltd, Leeds, UK., Axelsen MB; Novo Nordisk A/S, Søborg, Denmark., Kvist T; Novo Nordisk A/S, Søborg, Denmark., Blundell J; Institute of Psychological Sciences, Faculty of Medicine and Health, University of Leeds, Leeds, UK.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Mar; Vol. 20 (3), pp. 610-619. Date of Electronic Publication: 2017 Oct 27.